Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
Urbino I, Secreto C, Apolito V, Olivi M, Arrigo G, Boscaro E, Catania FM, D'Ardia S, Frairia C, Giai V, Freilone R, Bruno B, Lanzarone G, Giaccone L, Busca A, Dellacasa CM, Ferrero D, Audisio E, Cerrano M. Urbino I, et al. Among authors: olivi m. Leuk Res. 2024 Jan;136:107421. doi: 10.1016/j.leukres.2023.107421. Epub 2023 Nov 18. Leuk Res. 2024. PMID: 38042648 No abstract available.
Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
Apolito V, Arrigo G, Vasseur L, Olivi M, Perrone S, Giai V, Secreto C, Di Biase F, De Simone MC, Copia C, Gravetti A, Freilone R, Bruno B, Lanzarone G, Beggiato E, Frairia C, Audisio E, D'Ardia S, Ferrero D, Cerrano M, Ferrara F. Apolito V, et al. Among authors: olivi m. Br J Haematol. 2023 Nov;203(4):e98-e101. doi: 10.1111/bjh.19022. Epub 2023 Aug 2. Br J Haematol. 2023. PMID: 37533098 No abstract available.
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.
Martella F, Cerrano M, Di Cuonzo D, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, Lanzarone G, Urbino I, Freilone R, Giaccone L, Busca A, Dellacasa CM, Audisio E, Ferrero D, Beggiato E. Martella F, et al. Among authors: olivi m. Ann Hematol. 2022 Apr;101(4):855-867. doi: 10.1007/s00277-022-04770-6. Epub 2022 Feb 7. Ann Hematol. 2022. PMID: 35128571
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I, Zappasodi P, La Starza R, Fracchiolla NS, Chiusolo P, Giaccone L, Del Principe MI, Giglio F, Defina M, Favre C, Rizzari C, Castella B, Pizzolo G, Ferrara F, Chiaretti S, Foà R. Cerrano M, et al. Among authors: olivi m. Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851. Haematologica. 2022. PMID: 35021604 Free PMC article. No abstract available.
Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021.
Urbino I, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, Aydin S, Freilone R, Dellacasa C, Giaccone L, Ferrero D, Audisio E, Busca A, Cerrano M. Urbino I, et al. Among authors: olivi m. Cancers (Basel). 2021 Oct 11;13(20):5075. doi: 10.3390/cancers13205075. Cancers (Basel). 2021. PMID: 34680226 Free PMC article. Review.
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.
Ragaini S, Wagner S, Marconi G, Parisi S, Sartor C, Nanni J, Cristiano G, Talami A, Olivi M, Ocadlikova D, Ciciarello M, Corradi G, Ottaviani E, Papayannidis C, Paolini S, Vadakekolathu J, Cavo M, Rutella S, Curti A. Ragaini S, et al. Among authors: olivi m. Blood Adv. 2022 Jan 11;6(1):87-99. doi: 10.1182/bloodadvances.2021004878. Blood Adv. 2022. PMID: 34535017 Free PMC article.
69 results